F
Flare Therapeutics
Bringing an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines
About Flare Therapeutics
Flare Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on the development of small molecules designed to regain control of transcription factors that are often hijacked by cancer cells. This innovative approach has the potential to significantly alter the way diseases, particularly cancer, are treated.
Read full description
Flare Therapeutics serves a broad range of clients, primarily in the healthcare and medical research sectors. These include hospitals, research institutions, and potentially pharmaceutical companies interested in novel cancer treatments. The company operates in the highly competitive and rapidly evolving biotechnology market, where innovation and scientific breakthroughs are key to success.
The business model of Flare Therapeutics revolves around research and development of these small molecules. Once developed, these molecules can be patented and sold to healthcare providers or licensed to pharmaceutical companies for further development and commercialization. The company generates revenue through these sales and licensing agreements.
Recently, Flare Therapeutics presented new translational data in support of its lead asset, FX-909, for the treatment of Muscle-Invasive Urothelial Cancer (MIUC) at the SITC 2023 Annual Meeting. The company proposed targeting PPARG, a type of transcription factor, to overcome resistance to immunotherapy in MIUC treatment.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 63
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2026 | $85M | $340M | Agent Capital · Eli Lilly · Boxer Capital · Pfizer Ventures | ↗ |
| SERIES BOther financing | Mar 2023 | $123M | $492M | Memorial Sloan - Kettering Cancer Center · Eventide Asset Management · Agent Capital · ShangBay Capital | ↗ |
Growth signals
Latest recorded traffic for Flare Therapeutics is 3.8K monthly website visits, down 13.6% over the last three months. Flare Therapeutics's team declined 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Third Rock Ventures
Nextech Invest
Invus
Casdin Capital
Eventide Asset Management
Boxer Capital- PVPfizer Ventures
GordonMD Global Investment
Memorial Sloan - Kettering Cancer Center
Agent Capital
ShangBay Capital
Eli Lilly
Pavilion Capital Partners
Novartis
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Flare Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Flare Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.